Background
==========

Spinal fusion is a widely used procedure for spinal columns that demonstrate pathological instability. Although autogenous bone graft is still the gold standard for spinal fusion, there are concerns arising from associated donor site morbidity and inadequate tissue availability \[[@b1-medscimonit-23-3578]\]. Allografts and xenografts have been used as alternative methods. However, these methods suffer from risks of disease transmission and rejection \[[@b2-medscimonit-23-3578]\]. To overcome these problems, bone tissue engineering has been introduced in an attempt to provide an alternative option.

Platelet-rich plasma (PRP) is an autologous blood product that contains concentrated platelets, and these platelets can release growth factors at concentrations significantly higher than baseline blood levels, including platelet-derived growth factor (PDGF), transforming growth factor (TGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), fibroblast growth factor (FGF), and epidermal growth factor (EGF) \[[@b3-medscimonit-23-3578]--[@b5-medscimonit-23-3578]\]. Many of these growth factors are universally known to have beneficial effects on osteogenesis, and the use of PRP has been demonstrated to promote bone tissue regeneration \[[@b6-medscimonit-23-3578]--[@b10-medscimonit-23-3578]\]. Therefore, PRP is considered a promising option for autogenous bone graft used in spinal fusion \[[@b11-medscimonit-23-3578]\].

PRP preparation usually begins with autologous venous blood collection. However, substantial intraoperative blood loss is frequently accompanied with spinal fusion, and the additional blood loss from venous blood collection may increase the need for transfusion, which may overwhelm the advantage of PRP as an autograft \[[@b12-medscimonit-23-3578],[@b13-medscimonit-23-3578]\]. Therefore, the addition of venous blood collection has been a challenge in the use of PRP for spinal fusion. Since intraoperative blood loss in spinal fusion is more than the blood needed for PRP preparation, preparing PRP from blood harvested intraoperatively might be a potential solution. The objective of this study was to compare the characteristics of PRP prepared from blood harvested intraoperatively to blood from venipuncture, in an attempt to develop an option to provide a safe, simple, and cost-efficient approach for the preparation of PRP used in spinal fusion.

Material and Methods
====================

Participant recruitment
-----------------------

This study was performed in accordance with the principles of Declaration of Helsinki. The Independent Ethics Committee of Shanghai East Hospital Affiliated to Tongji University approved the protocols of this study. Written informed consent was obtained from each volunteer.

Between March 2013 and October 2015, a total of 20 patients treated with spinal fusion in our department were recruited for intraoperative blood donation (group A), and 20 healthy volunteers were recruited for venous blood donation (group B). The inclusion criterion was adults who agreed to participate in the study. The exclusion criteria were platelet concentration lower than 150×10^9^/L, a medical history of relevant diseases, use of any medications known to affect platelet function or concentration for 21 days prior to blood donation, and less than 100 mL of intraoperatively harvested blood.

Blood collection
----------------

For volunteers of group A, intraoperative blood was harvested by gentle aspiration in the presence of acid-citrate dextrose solution A (ACD-A). Then, the harvested blood was filtered with a 70-mm cell strainer to remove bone debris. For volunteers of group B, venous blood was collected by venipuncture and anticoagulated with ACD-A at the same ratio.

PRP preparation
---------------

PRP was prepared with WEGO PRP preparation system (WEGO, Weihai, China), which is the only commercial PRP preparation system approved by the China Food and Drug Administration, and PRP was prepared according to manufacturer's instructions. In brief, 35 mL of anticoagulated whole blood was spun at 400 g for 10 minutes. After the first-spin, the anticoagulated whole blood was separated into three components: platelet-containing plasma at the top, buffy coat in the middle, and erythrocytes at the bottom. Then, erythrocytes were removed from the centrifuge tube and discarded, and platelet-containing plasma and buffy coat were spun again at 400 g for 10 minutes. After the second-spin, the supernatant platelet-poor plasma was removed, and the remaining plasma and precipitated platelets were blended evenly to obtain a total of 4 mL of PRP.

Whole blood analysis
--------------------

Platelet concentrations in whole blood and PRP samples were evaluated by whole blood analysis using an automatic hematology analyzer (XS-800i, Sysmex, Kobe, Japan) in the clinical laboratory within 30 minutes after collection.

Enzyme-linked immunosorbent assay (ELISA)
-----------------------------------------

ELISA was performed to quantify PDGF-AB and TGF-β1 concentrations in activated PRP samples as described elsewhere \[[@b14-medscimonit-23-3578]\]. Briefly, PRP samples were incubated in 10% calcium chloride (final concentration 22.8 mM) for seven days at 37°C in a humidified atmosphere with 5% CO~2~. Then, the formulations were spun at 2800 g for 15 minutes to collect the supernatant. PDGF-AB and TGF-β1 concentrations in the supernatant were determined using the Quantikine Human Immunoassay kits (R&D Systems, Minneapolis, MN, USA) according to manufacturer's instructions.

Isolation and expansion of cells
--------------------------------

Human bone marrow-derived mesenchymal stem cells (HBMSCs) were isolated according to the protocols described previously \[[@b15-medscimonit-23-3578]\]. Briefly, bone marrow aspirates were harvested during femur fracture surgery. After removing bone debris by filtering, the cells were cultured in 75-cm^2^ flasks at the density of 5.0×10^5^ cells/flask in α-modification of minimum essential medium (α-MEM; Sigma-Aldrich, St Louis, MO, USA) containing 10% fetal bovine serum (FBS) (Gibco, Carlsbad, CA, USA) and 1% antibiotics (penicillin G and streptomycin) (Gibco) at 37°C in a humidified atmosphere with 5% CO~2~. The medium was changed after 48 hours to remove non-adherent cells, and thereafter changed every three days. Cells passages between three and five were used in this study.

CCK-8 assay
-----------

HBMSCs were seeded in 96-well plates at a density of 5,000 cells/well and serum-starved for 24 hours. Then, cells were cultured in medium supplemented with 10% of FBS or PRP prepared from harvested intraoperatively blood or venous blood for seven days. At the end of the incubation period, 10 μL of CCK-8 solution (Dojindo, Kumamoto, Japan) was added into each well containing 100 μL of medium and incubated for three hours. The absorbance value at 450 nm was measured using a microplate reader (Bio-Rad, Hercules, CA, USA).

Live/dead staining
------------------

HBMSCs were seeded in 6-well plates at a density of 1.0×10^5^ cells/well, serum-starved for 24 hours, and cultured in medium supplemented with 10% of FBS or PRP for seven days. Then, cells were stained with a Cell Viability Imaging Kit (Life Technologies, Gaithersburg, MD, USA) according to manufacturer's instructions. The percentages of viable cells were counted and calculated on five randomly selected fields per well.

Statistical analysis
--------------------

The data were analyzed with SPSS 22.0 (IBM, Chicago, IL, USA) and presented as means ± standard deviation or numbers of volunteers. Chi-square test or independent-samples Student's *t*-test was performed to analyze difference between groups as appropriate, and one-way analysis of variance (ANOVA) and Bonferroni post-hoc test were performed to analyze difference among groups. Correlations between platelet concentrations and growth factor concentrations were evaluated by Pearson correlation analysis. Significance was set a *p*\<0.05.

Results
=======

General information
-------------------

General information of grouped volunteers is shown in [Table 1](#t1-medscimonit-23-3578){ref-type="table"}; there was no significant difference in gender and age between groups.

Platelet concentrations in whole blood and PRP
----------------------------------------------

The mean whole blood platelet concentrations of group A and group B were 209.15±27.88×10^9^/L and 195.60±38.64, respectively, and the mean PRP platelet concentrations of group A and group B were 1046.90±237.28×10^9^/L and 932.55±234.1×10^9^/L, respectively. Group A and group B had similar platelet concentrations in whole blood (*p*=0.211, [Figure 1A](#f1-medscimonit-23-3578){ref-type="fig"}) and PRP (*p*=0.133, [Figure 1B](#f1-medscimonit-23-3578){ref-type="fig"}).

Growth factors concentrations in PRP
------------------------------------

The mean PDGF-AB and TGF-β1 concentrations in PRP were 40.23±8.17 ng/mL and 92.82±20.84 ng/mL, respectively, in group A; and 38.80±7.43 ng/mL and 96.40±23.86 ng/mL, respectively, in group B. Also, there was no significant difference between groups with regard to PDGF-AB concentrations (*p*=0.566, [Figure 2A](#f2-medscimonit-23-3578){ref-type="fig"}) and TGF-β1 concentrations (*p*=0.616, [Figure 2B](#f2-medscimonit-23-3578){ref-type="fig"}).

Correlations between platelet and growth factors concentrations
---------------------------------------------------------------

There were significantly positive correlations between whole blood platelet concentration and PRP platelet concentration (r=0.504, *p*=0.001, [Figure 3A](#f3-medscimonit-23-3578){ref-type="fig"}), PDGF-AB concentration (r=0.492, *p*=0.001, [Figure 3B](#f3-medscimonit-23-3578){ref-type="fig"}) and TGF-β1 concentration (r=0.789, *p*\<0.001, [Figure 3C](#f3-medscimonit-23-3578){ref-type="fig"}). Also, there were significantly positive correlations between PRP platelet concentration and PDGF-AB concentration (r=0.729, *p*\<0.001, [Figure 3D](#f3-medscimonit-23-3578){ref-type="fig"}) and TGF-β1 concentration (r=0.476, *p*=0.002, [Figure 3E](#f3-medscimonit-23-3578){ref-type="fig"}).

Effects of PRP on cell proliferation and viability
--------------------------------------------------

As shown in [Figure 4A](#f4-medscimonit-23-3578){ref-type="fig"}, results of the CCK-8 assay demonstrated that both PRP formulations promoted cell proliferation compared with FBS, but there was no significant difference between PRP formulations of group A and group B.

Quantified results of live/dead staining are shown in [Figure 4B](#f4-medscimonit-23-3578){ref-type="fig"}. Similar to the results of cell proliferation, both PRP formulations enhanced cell viability compared with FBS, but no significant difference was observed between PRP formulations of group A and group B.

Discussion
==========

Intraoperative blood harvest is part of routine management in patients undergoing major surgery with anticipated considerable blood loss. Multiple commercial systems for intraoperative blood harvest are available today. However, blood harvested by these systems barely has active platelets, and therefore, is not qualified for PRP preparation \[[@b16-medscimonit-23-3578]\]. Thus, we harvested intraoperative blood directly by a syringe prefilled with anticoagulant, rather than using a commercial intraoperative blood harvest system. Our results showed that blood harvested intraoperatively in this study had comparable platelet concentration compared with venous blood collected from healthy volunteers by venipuncture. Moreover, PRP prepared from harvested blood also had comparable platelet concentration compared with PRP prepared from venous blood, and there was a close correlation between platelet concentrations in whole blood and PRP. Therefore, it is plausible to conclude that the harvested blood potentially qualifies for PRP preparation.

The basis of PRP therapy is believed to be growth factors released from platelets \[[@b17-medscimonit-23-3578]--[@b19-medscimonit-23-3578]\]. Thus, the concentrations of growth factors in PRP were quantified in this study to clarify whether PRP formulations that were similar in platelet concentration were also similar in concentration of growth factors. PDGF-AB is a potent chemokine and regulator of cell proliferation and extracellular matrix deposition \[[@b20-medscimonit-23-3578],[@b21-medscimonit-23-3578]\] while TGF-β1 is involved in cell proliferation and apoptosis, as well as extracellular matrix deposition \[[@b22-medscimonit-23-3578],[@b23-medscimonit-23-3578]\]. Moreover, PDGF-AB and TGF-β1 have been shown to promote bone regeneration through enhanced osteogenesis \[[@b6-medscimonit-23-3578],[@b7-medscimonit-23-3578]\]. Although other growth factors, such as IGF, FGF, and EGF, also have been detected consistently in PRP and demonstrated to have beneficial effects on cell proliferation and bone matrix synthesis \[[@b23-medscimonit-23-3578]\], they were found to have much more variable concentrations in whole blood, and therefore in PRP \[[@b24-medscimonit-23-3578]\]. As a result, only PDGF-AB and TGF-β1 were selected to characterize PRP formulations prepared from whole blood harvested intraoperatively or by venipuncture. Our findings showed that PRP prepared from the harvested blood and venous blood also had similar concentrations for growth factors. Additional analysis revealed that the similar platelet concentrations in whole blood and PRP between groups resulted in the similar concentrations of growth factors in PRP. These findings indicated that the harvested blood could be used to prepare a PRP that has similar cellular and growth factor components compared with PRP prepared from venous blood, and therefore, the blood harvested intraoperatively may qualify for PRP preparation, as long as enough active platelets are also harvested.

However, similar therapeutic effects may not be the direct result of these similar platelet and growth factors concentrations, as the correlations between components and therapeutic effects of PRP might be not linear \[[@b25-medscimonit-23-3578]--[@b28-medscimonit-23-3578]\]. Therefore, the effects of PRP prepared from harvested blood and venous blood on cells were evaluated in this study. Our results demonstrated that PRP prepared from harvested blood and venous blood had similar effects on promoting proliferation and enhancing viability of HBMSCs. It is universally known that HBMSCs proliferation and viability are beneficial for tissue regeneration in bone or osteochondral lesions \[[@b29-medscimonit-23-3578],[@b30-medscimonit-23-3578]\]. Therefore, PRP prepared from harvested blood and venous blood may have similar outcomes in spinal fusion. Further studies are needed to substantiate this *in vivo* and *in vitro*.

Conclusions
===========

In this study, we demonstrated that intraoperatively harvested whole blood and whole blood collected by venipuncture were similar in platelet concentrations. Besides that, PRP formulations prepared from both kinds of whole blood were similar in concentrations of platelets and growth factors. Additional analysis showed that the similar concentrations of growth factors resulted from the similar platelet concentrations of whole blood and PRP between the two groups. Moreover, these two kinds of PRP formulations had similar effects on promoting cell proliferation and enhancing cell viability. Therefore, intraoperatively harvested whole blood may be a potential option for preparing PRP for spinal fusion. However, considering the small sample included in this study, further study with a larger sample size is needed to substantiate this *in vivo* and *in vitro*.
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###### 

General information of grouped volunteers.

                          Group A      Group B      *p* value
  ----------------------- ------------ ------------ -----------
  Number of volunteers    20           20           
  Gender (Male: Female)   11: 9        13: 7        0.748
  Age (years)             51.35±7.26   49.95±9.54   0.604
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